Published in J Steroid Biochem Mol Biol on December 01, 1998
The properties of high-dimensional data spaces: implications for exploring gene and protein expression data. Nat Rev Cancer (2008) 3.43
Gene network signaling in hormone responsiveness modifies apoptosis and autophagy in breast cancer cells. J Steroid Biochem Mol Biol (2009) 1.26
Genetic ablation of caveolin-1 drives estrogen-hypersensitivity and the development of DCIS-like mammary lesions. Am J Pathol (2009) 1.05
LAS1L interacts with the mammalian Rix1 complex to regulate ribosome biogenesis. Mol Biol Cell (2011) 1.03
Genome-wide analysis of interferon regulatory factor I binding in primary human monocytes. Gene (2011) 0.96
An extensive tumor array analysis supports tumor suppressive role for nucleophosmin in breast cancer. Am J Pathol (2011) 0.86
Intrinsically disordered regions of nucleophosmin/B23 regulate its RNA binding activity through their inter- and intra-molecular association. Nucleic Acids Res (2013) 0.83
Regulation of subcellular distribution and oncogenic potential of nucleophosmin by plakoglobin. Oncogenesis (2012) 0.81
Deregulated expression of Nucleophosmin 1 in gastric cancer and its clinicopathological implications. BMC Gastroenterol (2014) 0.81
Transcriptomic signature of bexarotene (rexinoid LGD1069) on mammary gland from three transgenic mouse mammary cancer models. BMC Med Genomics (2008) 0.80
HEXIM1, a New Player in the p53 Pathway. Cancers (Basel) (2013) 0.77
Estrogen mediated expression of nucleophosmin 1 in human endometrial carcinoma clinical stages through estrogen receptor-α signaling. Cancer Cell Int (2014) 0.76
Humoral autoimmune response to nucleophosmin in the immunodiagnosis of hepatocellular carcinoma. Oncol Rep (2015) 0.75
Changes in the in vitro activity of platinum drugs when administered in two aliquots. BMC Cancer (2016) 0.75
Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet (2013) 9.46
Breast cancer (1) N Engl J Med (1992) 4.79
Evidence that transforming growth factor-beta is a hormonally regulated negative growth factor in human breast cancer cells. Cell (1987) 3.45
Ten-year results of a comparison of conservation with mastectomy in the treatment of stage I and II breast cancer. N Engl J Med (1995) 3.43
Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines. J Cell Physiol (1992) 3.15
Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol (1990) 3.12
Clonogenic and nonclonogenic in vitro chemosensitivity assays. Cancer Treat Rep (1985) 2.97
Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance. J Natl Cancer Inst (1997) 2.88
erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst (1998) 2.85
Sequence heterogeneity of the eae gene and detection of verotoxin-producing Escherichia coli using serotype-specific primers. Epidemiol Infect (1994) 2.70
Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat (2001) 2.26
Cerebral hemispheric asymmetry in humans. Cortical speech zones in 100 adults and 100 infant brains. Arch Neurol (1975) 2.21
The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res (2000) 2.09
Quantitative effects on cardiovascular risk factors and coronary heart disease risk of replacing partially hydrogenated vegetable oils with other fats and oils. Eur J Clin Nutr (2009) 2.07
Estrogenic regulation of growth and polypeptide growth factor secretion in human breast carcinoma. Endocr Rev (1987) 2.07
Mechanism of action of glucocorticoids. Metabolism (1974) 2.04
Direct interaction of a ligand for the erbB2 oncogene product with the EGF receptor and p185erbB2. Science (1990) 2.00
Homocysteine, MTHFR and risk of venous thrombosis: a meta-analysis of published epidemiological studies. J Thromb Haemost (2005) 1.99
Establishment and characterization of three new continuous cell lines derived from human breast carcinomas. Cancer Res (1978) 1.97
LIGHT, a novel ligand for lymphotoxin beta receptor and TR2/HVEM induces apoptosis and suppresses in vivo tumor formation via gene transfer. J Clin Invest (1998) 1.89
Mastectomy versus breast-conserving therapy in the treatment of stage I and II carcinoma of the breast: a randomized trial at the National Cancer Institute. J Clin Oncol (1992) 1.89
Development of verotoxin 2- and verotoxin 2 variant (VT2v)-specific oligonucleotide probes on the basis of the nucleotide sequence of the B cistron of VT2v from Escherichia coli E32511 and B2F1. J Clin Microbiol (1991) 1.88
High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res (1993) 1.86
Independent prognostic value of eosinophil and mast cell infiltration in colorectal cancer tissue. J Pathol (1999) 1.86
Psychosocial and physical outcomes of primary breast cancer therapy: mastectomy vs excisional biopsy and irradiation. Breast Cancer Res Treat (1983) 1.80
Structural basis for the conducting interface between LaAlO3 and SrTiO3. Phys Rev Lett (2007) 1.76
MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen. Cancer Res (1997) 1.74
Epidermal growth factor receptor gene expression in estrogen receptor-positive and negative human breast cancer cell lines. Mol Endocrinol (1987) 1.72
Breast conservation versus mastectomy: distress sequelae as a function of choice. J Clin Oncol (1989) 1.70
Serum cystatin C, a new marker of glomerular filtration rate, is increased during malignant progression. Clin Chem (1998) 1.65
Analysis of insulin-like growth factor I gene expression in malignancy: evidence for a paracrine role in human breast cancer. Mol Endocrinol (1989) 1.65
Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays. J Pharmacol Exp Ther (2001) 1.64
Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis. J Natl Cancer Inst (1999) 1.64
Synthesis and secretion of platelet-derived growth factor by human breast cancer cell lines. Proc Natl Acad Sci U S A (1987) 1.61
Breast cancer risk in rats fed a diet high in n-6 polyunsaturated fatty acids during pregnancy. J Natl Cancer Inst (1996) 1.60
A maternal diet high in n - 6 polyunsaturated fats alters mammary gland development, puberty onset, and breast cancer risk among female rat offspring. Proc Natl Acad Sci U S A (1997) 1.60
Clinical electron-beam dosimetry: report of AAPM Radiation Therapy Committee Task Group No. 25. Med Phys (1991) 1.60
Expression of transforming growth factor alpha and its messenger ribonucleic acid in human breast cancer: its regulation by estrogen and its possible functional significance. Mol Endocrinol (1988) 1.59
Secretion of an insulin-like growth factor-I-related protein by human breast cancer cells. Cancer Res (1986) 1.58
C-terminal deletion mutants of the FokI restriction endonuclease. Gene (1993) 1.58
Preoperative plasma plasminogen activator inhibitor type-1 and serum C-reactive protein levels in patients with colorectal cancer. The RANX05 Colorectal Cancer Study Group. Ann Surg Oncol (2000) 1.58
Insulin-like growth factor receptor expression and function in human breast cancer. Cancer Res (1990) 1.57
Oestrogen-responsive human breast cancer in long term tissue culture. Nature (1975) 1.56
Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res (1994) 1.55
The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer. N Engl J Med (1978) 1.54
Neoadjuvant chemotherapy in the combined modality approach of locally advanced nonmetastatic breast cancer. Cancer Res (1987) 1.54
Soluble vascular endothelial growth factor levels in patients with primary colorectal carcinoma. The Danish RANX05 Colorectal Cancer Study Group. Eur J Surg Oncol (2000) 1.48
Impact of lipoprotein(a) levels and apolipoprotein(a) isoform size on risk of coronary heart disease. J Intern Med (2014) 1.48
Cystatin C and risk of vascular and nonvascular mortality: a prospective cohort study of older men. J Intern Med (2010) 1.47
Immunoconjugates of geldanamycin and anti-HER2 monoclonal antibodies: antiproliferative activity on human breast carcinoma cell lines. J Natl Cancer Inst (2000) 1.46
Characterization of estrogen responsive transforming activity in human breast cancer cell lines. Cancer Res (1986) 1.44
Coherent control of pulsed X-ray beams. Nature (2001) 1.41
Estrogen-induced factors of breast cancer cells partially replace estrogen to promote tumor growth. Science (1986) 1.41
Homocysteine and brain atrophy on MRI of non-demented elderly. Brain (2003) 1.40
Holistic vets must prove their treatments. Aust Vet J (2001) 1.40
Breast cancer (2). N Engl J Med (1992) 1.39
The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients. Cancer Res (1998) 1.38
Growth factors in breast cancer. Endocr Rev (1995) 1.37
On the constancy of the number of villi in the duodenum of the post-embryonic domestic fowl. J Embryol Exp Morphol (1967) 1.37
Vestibular control of sympathetic activity. An otolith-sympathetic reflex in humans. Exp Brain Res (2002) 1.36
Growth factor messenger RNA expression by human breast fibroblasts from benign and malignant lesions. Cancer Res (1991) 1.36
Distribution, frequency, and quantitative analysis of estrogen, progesterone, androgen, and glucocorticoid receptors in human breast cancer. Cancer Res (1979) 1.35
Changes in multiple or sequential estrogen receptor determinations in breast cancer. Cancer (1980) 1.34
ATP binding cassette transporters and drug resistance in breast cancer. Endocr Relat Cancer (2003) 1.32
MCF7/LCC2: a 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780. Cancer Res (1993) 1.32
Hormone responsive human breast cancer in long-term tissue culture: effect of insulin. Proc Natl Acad Sci U S A (1976) 1.32
Acquisition of hormone-independent growth in MCF-7 cells is accompanied by increased expression of estrogen-regulated genes but without detectable DNA amplifications. Cancer Res (1993) 1.32
Insulin-like growth factor II mRNA expression in human breast cancer. Cancer Res (1988) 1.32
Effects of antiestrogens on the estrogen-regulated pS2 RNA and the 52- and 160-kilodalton proteins in MCF7 cells and two tamoxifen-resistant sublines. J Biol Chem (1984) 1.31
Regulation of the estrogen receptor in MCF-7 cells by estradiol. Mol Endocrinol (1988) 1.31
Cysteine proteinase inhibitors stefin A, stefin B, and cystatin C in sera from patients with colorectal cancer: relation to prognosis. Clin Cancer Res (2000) 1.31
Association of MMP-2 activation potential with metastatic progression in human breast cancer cell lines independent of MMP-2 production. J Natl Cancer Inst (1993) 1.30
Characterization of the human and mouse HEY1, HEY2, and HEYL genes: cloning, mapping, and mutation screening of a new bHLH gene family. Genomics (2000) 1.30
Prepubertal exposure to zearalenone or genistein reduces mammary tumorigenesis. Br J Cancer (1999) 1.30
Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma. Cancer Res (1994) 1.28
High preoperative plasma tissue inhibitor of metalloproteinase-1 levels are associated with short survival of patients with colorectal cancer. Clin Cancer Res (2000) 1.27
Association between steroid hormone receptor status and disease-free interval in breast cancer. Cancer Treat Rep (1979) 1.27
Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness. Clin Exp Metastasis (1996) 1.27
Angiopoietin-1 and its receptor Tie-2 participate in the regulation of capillary-like tubule formation and survival of endothelial cells. Microvasc Res (1999) 1.26
Transfection of v-rasH DNA into MCF-7 human breast cancer cells bypasses dependence on estrogen for tumorigenicity. Science (1985) 1.26
Digitized mammography: a clinical trial of postmenopausal women randomly assigned to receive raloxifene, estrogen, or placebo. J Natl Cancer Inst (2001) 1.26
ELISA determination of soluble urokinase receptor in blood from healthy donors and cancer patients. Clin Chem (1997) 1.26
Oestrogen receptors in human malignant melanoma. Lancet (1976) 1.26
Ribozyme-mediated down-regulation of ErbB-4 in estrogen receptor-positive breast cancer cells inhibits proliferation both in vitro and in vivo. Cancer Res (1999) 1.25
Expression and function of angiopoietin-1 in breast cancer. Br J Cancer (2000) 1.24
Quantitation of TIMP-1 in plasma of healthy blood donors and patients with advanced cancer. Br J Cancer (1999) 1.24
Tissue inhibitor of metalloproteinases-1 in breast cancer. Endocr Relat Cancer (2005) 1.24
Free healthy breakfasts in primary schools: a cluster randomised controlled trial of a policy intervention in Wales, UK. Public Health Nutr (2010) 1.24
Oncogene-induced basement membrane invasiveness in human mammary epithelial cells. Clin Exp Metastasis (1994) 1.24
Homocysteine and cognitive function in the elderly: the Rotterdam Scan Study. Neurology (2002) 1.24
Overexpression of KAI1 suppresses in vitro invasiveness and in vivo metastasis in breast cancer cells. Cancer Res (2001) 1.23
Differences in transferrin response and numbers of transferrin receptors in rat and human mammary carcinoma lines of different metastatic potentials. J Cell Physiol (1993) 1.23